248 related articles for article (PubMed ID: 24954865)
1. A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma.
Aihara A; Huang CK; Olsen MJ; Lin Q; Chung W; Tang Q; Dong X; Wands JR
Hepatology; 2014 Oct; 60(4):1302-13. PubMed ID: 24954865
[TBL] [Abstract][Full Text] [Related]
2. Aspartate β-hydroxylase modulates cellular senescence through glycogen synthase kinase 3β in hepatocellular carcinoma.
Iwagami Y; Huang CK; Olsen MJ; Thomas JM; Jang G; Kim M; Lin Q; Carlson RI; Wagner CE; Dong X; Wands JR
Hepatology; 2016 Apr; 63(4):1213-26. PubMed ID: 26683595
[TBL] [Abstract][Full Text] [Related]
3. ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis.
Lin Q; Chen X; Meng F; Ogawa K; Li M; Song R; Zhang S; Zhang Z; Kong X; Xu Q; He F; Bai X; Sun B; Hung MC; Liu L; Wands J; Dong X
Mol Cancer; 2019 Nov; 18(1):156. PubMed ID: 31694640
[TBL] [Abstract][Full Text] [Related]
4. Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression.
Huang CK; Iwagami Y; Aihara A; Chung W; de la Monte S; Thomas JM; Olsen M; Carlson R; Yu T; Dong X; Wands J
PLoS One; 2016; 11(3):e0150336. PubMed ID: 26954680
[TBL] [Abstract][Full Text] [Related]
5. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
6. Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis.
Nagaoka K; Ogawa K; Ji C; Cao KY; Bai X; Mulla J; Cheng Z; Wands JR; Huang CK
Dig Dis Sci; 2021 Apr; 66(4):1080-1089. PubMed ID: 32445050
[TBL] [Abstract][Full Text] [Related]
7. Hydroxylase Activity of ASPH Promotes Hepatocellular Carcinoma Metastasis Through Epithelial-to-Mesenchymal Transition Pathway.
Zou Q; Hou Y; Wang H; Wang K; Xing X; Xia Y; Wan X; Li J; Jiao B; Liu J; Huang A; Wu D; Xiang H; Pawlik TM; Wang H; Lau WY; Wang Y; Shen F
EBioMedicine; 2018 May; 31():287-298. PubMed ID: 29764768
[TBL] [Abstract][Full Text] [Related]
8. Aspartate β-hydroxylase targeting in castration-resistant prostate cancer modulates the NOTCH/HIF1α/GSK3β crosstalk.
Barboro P; Benelli R; Tosetti F; Costa D; Capaia M; Astigiano S; Venè R; Poggi A; Ferrari N
Carcinogenesis; 2020 Sep; 41(9):1246-1252. PubMed ID: 32525968
[TBL] [Abstract][Full Text] [Related]
9. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
[TBL] [Abstract][Full Text] [Related]
10. Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma.
Shimoda M; Tomimaru Y; Charpentier KP; Safran H; Carlson RI; Wands J
J Hepatol; 2012 May; 56(5):1129-1135. PubMed ID: 22245894
[TBL] [Abstract][Full Text] [Related]
11. Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells.
Zhang S; Yang Y; Liang Z; Duan W; Yang J; Yan J; Wang N; Feng W; Ding M; Nie Y; Jin Z
PLoS One; 2013; 8(12):e83699. PubMed ID: 24386256
[TBL] [Abstract][Full Text] [Related]
12. Diverse molecular functions of aspartate β‑hydroxylase in cancer (Review).
Zheng W; Wang X; Hu J; Bai B; Zhu H
Oncol Rep; 2020 Dec; 44(6):2364-2372. PubMed ID: 33125119
[TBL] [Abstract][Full Text] [Related]
13. INPP5F translocates into cytoplasm and interacts with ASPH to promote tumor growth in hepatocellular carcinoma.
Zhou Q; Lin J; Yan Y; Meng S; Liao H; Chen R; He G; Zhu Y; He C; Mao K; Wang J; Zhang J; Zhou Z; Xiao Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):13. PubMed ID: 34996491
[TBL] [Abstract][Full Text] [Related]
14. Aspartate β-Hydroxylase expression promotes a malignant pancreatic cellular phenotype.
Dong X; Lin Q; Aihara A; Li Y; Huang CK; Chung W; Tang Q; Chen X; Carlson R; Nadolny C; Gabriel G; Olsen M; Wands JR
Oncotarget; 2015 Jan; 6(2):1231-48. PubMed ID: 25483102
[TBL] [Abstract][Full Text] [Related]
15. Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness.
de la Monte SM; Tamaki S; Cantarini MC; Ince N; Wiedmann M; Carter JJ; Lahousse SA; Califano S; Maeda T; Ueno T; D'Errico A; Trevisani F; Wands JR
J Hepatol; 2006 May; 44(5):971-83. PubMed ID: 16564107
[TBL] [Abstract][Full Text] [Related]
16. Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma.
Xiong J; Wu JS; Mao SS; Yu XN; Huang XX
Oncol Rep; 2016 Sep; 36(3):1483-90. PubMed ID: 27460949
[TBL] [Abstract][Full Text] [Related]
17. TRIP6 promotes tumorigenic capability through regulating FOXC1 in hepatocellular carcinoma.
Wang F; Zhang B; Xu X; Zhu L; Zhu X
Pathol Res Pract; 2020 Apr; 216(4):152850. PubMed ID: 32046874
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
19. IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma.
Xu QG; Yu J; Guo XG; Hou GJ; Yuan SX; Yang Y; Yang Y; Liu H; Pan ZY; Yang F; Gu FM; Zhou WP
Mol Oncol; 2018 Jun; 12(6):936-952. PubMed ID: 29689643
[TBL] [Abstract][Full Text] [Related]
20. EYA4 serves as a prognostic biomarker in hepatocellular carcinoma and suppresses tumour angiogenesis and metastasis.
Gu F; Yuan S; Liu L; Zhu P; Yang Y; Pan Z; Zhou W
J Cell Mol Med; 2019 Jun; 23(6):4208-4216. PubMed ID: 30957411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
